Gene-Edited immune cells take on Hard-to-Treat blood cancer
Disease control
Recruiting now
This early-stage study tests a new treatment called CB-011 for people with multiple myeloma that has returned or stopped responding to other therapies. CB-011 uses CRISPR gene editing to create donor immune cells that target and attack cancer cells. The study aims to find the saf…
Phase: PHASE1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC